SCHEMBL7233267

SCHEMBL7233267

COc1cccnc1CC(C)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.43
CYP3A4 P08684 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PLAU P00749 1/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
TP53 P04637 2/20 0.42
PKM P14618 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
GAA P10253 1/20 0.41
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
LMNA P02545 1/20 0.41
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16364773 0.86 SMN1; SMN2 (0.50) ADORA2ATDP1PLAURAB9ANPC1
SCHEMBL29796455 0.86 SMN1; SMN2 (0.50) ADORA2ATDP1PLAURAB9ANPC1
SCHEMBL534151 0.85 MAPT (0.48) ADORA2ATDP1PLAURAB9ANPC1
SCHEMBL16320490 0.83 SYK (0.44) ADORA2ATDP1PLAURAB9ANPC1
SCHEMBL21455719 0.83 MTNR1A (0.48) ADORA2ATDP1PLAURAB9ANPC1
SCHEMBL932150 0.82 MAPT (0.58) TDP1RAB9ATP53SMN1; SMN2L3MBTL1
SCHEMBL506497 0.80 ALDH1A1 (0.55) ADORA2APLAURAB9ANPC1TP53
Hydrochloric Acid SCHEMBL11095592 0.78 ALDH1A1 (0.53) ADORA2APLAURAB9ANPC1TP53
SCHEMBL7235859 0.78 CYP3A4 (0.42) CYP3A4TDP1RAB9ASMN1; SMN2NFE2L2
SCHEMBL17061218 0.77 LMNA (0.53) ADORA2ARAB9ASMN1; SMN2POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112279805-B Process for preparing 1- (3-methoxypyridin-2-yl) -2-propanone 浙江金伯士药业有限公司 2022-03-22 CN claimed
CN-112279805-A Process for preparing 1- (3-methoxypyridin-2-yl) -2-propanone 浙江金伯士药业有限公司 2021-01-29 CN claimed
CN-1651428-A Preparation method of hydrobromic acid antifebrile dichroanone SHANGHAI YINNUO BIOCHEMICAL SC (CN) 2005-08-10 CN claimed
US-20230192614-A1 METHOD FOR PREPARATION OF TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-PROPANONE AS INTERMEDIATE OF HALOFUGINONE CHENGDA PHARMACEUTICALS CO., LTD. (CN) 2023-06-22 US disclosed
WO-2023065610-A1 PREPARATION METHOD FOR HALOFUGINONE INTERMEDIATE TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-ACETONE 诚达药业股份有限公司 2023-04-27 WO disclosed
CN-112279805-B Process for preparing 1- (3-methoxypyridin-2-yl) -2-propanone 浙江金伯士药业有限公司 2022-03-22 CN disclosed
CN-112279805-B Process for preparing 1- (3-methoxypyridin-2-yl) -2-propanone 浙江金伯士药业有限公司 2022-03-22 CN disclosed
CN-112279805-A Process for preparing 1- (3-methoxypyridin-2-yl) -2-propanone 浙江金伯士药业有限公司 2021-01-29 CN disclosed
CN-112279805-A Process for preparing 1- (3-methoxypyridin-2-yl) -2-propanone 浙江金伯士药业有限公司 2021-01-29 CN disclosed
US-9714234-B2 Carbazole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2017-07-25 US disclosed
US-20160200710-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2016-07-14 US disclosed
CN-103664741-B Preparation method of 2-acetonyl-3-methoxypiperidine GUANGZHOU WISDOM BIO TECHNOLOGY CO LTD 2015-04-29 CN disclosed
CN-1304391-C Preparation method of hydrobromic acid antifebrile dichroanone SHANGHAI YINNUO BIOCHEMICAL SC (CN) 2007-03-14 CN disclosed
CN-1651428-A Preparation method of hydrobromic acid antifebrile dichroanone SHANGHAI YINNUO BIOCHEMICAL SC (CN) 2005-08-10 CN disclosed
US-6521643-B1 Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-18 US disclosed
EP-1157022-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-28 EP disclosed
WO-2000049015-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-08-24 WO disclosed
US-4797486-A ANTIPROTOZOA AGENTS PFIZER INC. (US) 1989-01-10 US disclosed
US-4725599-A POULTRY PFIZER INC. (US) 1988-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200710-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS BTK, CNKSR1, SYK ADORA2A 3343/4885CYP3A4 2551/4885TDP1 1084/4885
US-20230192614-A1 METHOD FOR PREPARATION OF TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-PROPANONE AS INTERMEDIATE OF HALOFUGINONE TALDO1, RPL22, RPS20 ADORA2A 2060/4885CYP3A4 955/4885TDP1 4053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.